Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Feb 3;6(3):819–829. doi: 10.1002/sctm.16-0335

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Gamma‐secretase inhibitor IX (GSI) targets CD44⁺ cancer stem cells (CSCs) via Notch1. (A): We silenced CD44 using siRNA and confirmed the effect of GSI on hairy enhancer of split‐1, p‐Erk, p‐Akt, RAC1, Notch 1, c‐Myc, Stat3, P‐Stat3, wnt 5a/b, beta‐catenin by immunoblot. (B): We also silenced Notch1 using siRNA and confirmed the effect of GSI on same targets. β‐actin was used as a loading control. (C): Complete inhibition of nuclear translocation of beta‐catenin was also observed after GSI treatment in CD44⁺ CSCs using immuno blot. Alpha‐tubulin was used as loading control. Abbreviations: CE, cytoplasmic extracts; GSI, gamma‐secretase inhibitor IX; Hes1, hairy enhancer of split‐1; NE, nuclear extracts.